Shaily Engineering Plastics (501423) Q4 24/25 earnings summary

Executive summary

• Achieved highest ever consolidated revenues and profitability in FY25, with 22% YoY revenue growth to INR 787 crores and strong performance across all business segments.

• Expanded product portfolio and customer base in healthcare, consumer, and industrial segments, with multiple new contracts and business awards.

• Continued investments in capacity expansion, especially in pen manufacturing for drug delivery devices, and showcased innovations at major global exhibitions.

• Audited consolidated and standalone financial results for FY25 were reviewed and approved by the Board on May 13, 2025.

• Statutory auditors issued unmodified (clean) opinions on both standalone and consolidated results.

Financial highlights

• FY25 consolidated revenue grew 22% YoY to INR 786.8 crores; Q4 FY25 revenue up 28% YoY to INR 217.8 crores.

• EBITDA increased 45% YoY to INR 178.4 crores in FY25, with margin up 350 bps to 22.7%; PAT rose 63% YoY to INR 93.1 crores.

• Gross profit margin improved by 470 bps to 47.2% in FY25.

• Basic EPS (consolidated) for FY25 was ₹20.29, up from ₹12.49 in FY24.

• Debt to equity at 0.4x; long-term debt to equity at 0.07x.

Outlook and guidance

• Healthcare segment expected to comprise ~30% of revenues in coming years, with commercial supplies of GLP-1 pens to start in FY26.

• Targeting sales of 30–35 million pens in FY26, with ~70% growth in device volumes, mainly from IP-led platforms.

• CapEx of INR 150 crores planned for pen manufacturing expansion, with total CapEx for FY26 at INR 180–185 crores.

• Board recommended a dividend of ₹2 per fully paid equity share for FY25, subject to shareholder approval.

• Margin improvement expected year-over-year, not to be viewed on a quarterly baseline.